The mechanism of protracted wound healing on oral mucosa in diabetes. Review

Bosnian Journal of Basic Medical Sciences

Volumn 10, Issue 3, 2010, Pages 186-191

  Abiko, Yoshihiro ^a   Selimovic, Denis ^b  

^a HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Diabetes; Oral mucosa; Wound healing

Indexed keywords

EID: 77957165370     PISSN: 15128601     EISSN: None     Source Type: Journal    
DOI: 10.17305/bjbms.2010.2683     Document Type: Article

References (83)

1. Guo S., Dipietro L.A. Factors affecting wound healing. J. Dent. Res. 2010; 89: 219-229.
2. Huysman E., Mathieu C. Diabetes and peripheral vascular disease. Acta. Chir. Belg. 2009; 109: 587-594.
3. Mathieu D., Linke J.C., Wattel F. Non-healing wounds. In: Handbook on hyperbaric medicine, Mathieu DE, editor. Netherlands: Springer, 2006,401-427.
4. Woo K., Ayello E.A., Sibbald R.G. Ue edge effect: current therapeutic options to advance the wound edge. Adv. Skin. Wound. Care. 2007; 20:99-117.
5. Vincent A.M., Russell J.W., Low P., Feldman E.L. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr. Rev. 2004; 25: 612-628.
6. Huijberts M.S, Schaper N.C., Schalkwijk C.G. Advanced glyca-tion end products and diabetic foot disease. Diabetes. Metab. Res. Rev. 2008; 24(1): 19-24.
7. Fernandes R., Girao H., Pereira P. High glucose down-regulates intercellular communication in retinal endothelial cells by enhancing degradation of connexin 43 by a proteasome-dependent mechanism. J. Biol. Chem. 2004; 279: 27219-27224.
8. Lin D., Takemoto D.J. Oxidative activation of protein kinase Cgamma through the Ci domain. Effects on gap junctions. J. Biol. Chem. 2005; 280:13682-13693.
9. Lin H., Ogawa K., Imanaga I., Tribulova N. Remodeling of connexin 43 in the diabetic rat heart. Mol. Cell. Biochem. 2006; 290: 69-78.
10. Kowluru R.A., Chan P.S. Oxidative stress and diabetic retinopa-thy. Exp. Diabetes. Res. 2007: 43603,2007.
11. Roy S., Trudeau K., Roy S., Behl Y., Dhar S., Chronopoulos A. New insights into hyperglycemia-induced molecular changes in microvascular cells. J. Dent. Res. 2010; 89:116-127.
12. Esposito K., Nappo F., Marfella R. et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-2072.
13. Peleg A.Y., Weerarathna T., McCarthy J.S., Davis T.M. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes. Metab. Res. Rev. 2007; 23: 3-13.
14. Collison K.S., Parhar R.S., Saleh S.S. et al. RAGE-mediated neutro-phil dysfunction is evoked by advanced glycation end products (AGEs). J. Leukoc. Biol. 2002; 71: 433-444.
15. Delamaire M., Maugendre D., Moreno M., Le Goff M.C., Allan-nic H., Genetet B. Impaired leucocyte functions in diabetic patients. Diabet. Med. 1997; 14: 29-34.
16. Hill H.R., Augustine N.H., Rallison M.L., Santos J.I. Defective monocyte chemotactic responses in diabetes mellitus. J. Clin. Immunol. 1983; 3: 70-77.
17. Walrand S., Guillet C., Boirie Y., Vasson M.P. In vivo evidences that insulin regulates human polymorphonuclear neutrophil functions. J. Leukoc. Biol. 2004; 76:1104-1110.
18. Abiko Y., Saitoh M. Salivary defensins and their importance in oral health and disease. Curr. Pharm. Des. 2007; 13: 3065-3072.
19. Abiko Y., Saitoh M., Nishimura M., Yamazaki M., Sawamura D., Kaku T. Role of beta-defensins in oral epithelial health and disease. Med. Mol. Morphol. 2007; 40:179-184.
20. Barnea M., Madar Z., Froy O. Glucose and insulin are needed for optimal defensin expression in human cell lines. Biochem. Bio-phys. Res. Commun. 2008; 367: 452-456.
21. Hatakeyama S., Sato J., Shimizu Y. etal. Effect of diabetes related molecules on beta-defensins in keratinocyte. 88th general Session of the International Association for Dental Research. (Barcelona) 2010.
22. Van Nieuw Amerongen A., Bolscher J.G., Veerman E.C. Salivary proteins: protective and diagnostic value in cariology? Caries. Res. 2004, 38:247-253.
23. Martinuzzi E., Lemonnier F.A., Boitard C., Mallone R. Measurement of CD8 T cell responses in human type 1 diabetes. Ann. N.Y. Acad. Sci. 2008; 1150: 61-67.
24. Tsai S., Shameli A., Santamaria P. CD8+ cells in type 1 diabetes. Adv. Immunol. 2008; 100:179-124.
25. Dandona P., Aljada A., Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends. Immunol. 2004; 25: 4-7.
26. Preshaw P.M., Foster N., Taylor J.J. Cross-susceptibility between periodontal disease and type 2 diabetes mellitus: an immunobio-logical perspective. Periodontol 2000. 2007; 45:138-57.
27. Graves D.T., Liu R., Alikhani M., Al-Mashat H., Trackman P.C. Diabetes-enhanced inflammation and apoptosis-impact on periodontal pathology. J. Dent. Res. 2006; 85:15-21.
28. Soell M., Hassan M., Miliauskaite A., Haikel Y., Selimovic D. The oral cavity of elderly patients in diabetes. Diabetes. Metab. 2007; 33(1): 10-18.
29. Lalla E., Lamster I.B., Drury S., Fu C., Schmidt A.M. Hyperglyce-mia, glycoxidation and receptor for advanced glycation endprod-ucts: potential mechanisms underlying diabetic complications, including diabetes-associated periodontitis. Periodontol 2000. 2000; 23: 50-62.
30. Nienhuis H.L., WestraJ., Smit A.J., Limburg P.C., Kallenberg C.G., Bijl M. AGE and their receptor RAGE in systemic autoimmune diseases: an inflammation propagating factor contributing to accelerated atherosclerosis. Autoimmunity. 2009; 42: 302-304.
31. Ren L., Fu Y., Deng Y., Qi L., Jin L. Advanced glycation end products inhibit the expression of collagens type I and III by human gingival fibroblasts. J. Periodontol. 2009; 80:1166-1173.
32. Aydin S. A comparison of ghrelin, glucose, alpha-amylase and protein levels in saliva from diabetics. J. Biochem. Mol. Biol. 2007; 40: 29-35.
33. Jurysta C., Bulur N., Oguzhan B. et al. Salivary glucose concentration and excretion in normal and diabetic subjects. J. Biomed. Biotechnol. 2009:430426, 2009.
34. Yoon M.S., Jankowski V., Montag S. et al. Characterisation of advanced glycation endproducts in saliva from patients with diabetes mellitus. Biochem. Biophys. Res. Commun. 2004; 323: 377-381.
35. Sabino-Silva R., Freitas H.S., Lamers M.L., Okamoto M.M., Santos M.F., Machado U.F. Na+-glucose cotransporter SGLTi protein in salivary glands: potential involvement in the diabetes-induced decrease in salivary flow. J. Membr. Biol. 2009; 228: 63-69.
36. Bernardi M.J., Reis A., Loguercio A.D., Kehrig R., Leite M.F., Nicolau J. Study of the buffering capacity, pH and salivary flow rate in type 2 well-controlled and poorly controlled diabetic patients. Oral. Health. Prev. Dent. 2007; 5: 73-78.
37. Lin C.C., Sun S.S., Kao A. Lee C.C. Impaired salivary function in patients with noninsulin-dependent diabetes mellitus with xerostomia. J. Diabetes. Complications. 2002; 16:176-179.
38. Watanabe M., Yamagishi-Wang H., Kawaguchi M. Lowered susceptibility of muscarinic receptor involved in salivary secretion of streptozotocin-induced diabetic rats. Jpn. J. Pharmacol. 2001; 87: 117-124.
39. Mata A.D., Marques D., Rocha S. et al. Effects of diabetes mellitus on salivary secretion and its composition in the human. Mol. Cell. Biochem. 2004; 261:137-142.
40. Dodds M.W., Yeh C.K., Johnson D.A. Salivary alterations in type 2 (non-insulin-dependent) diabetes mellitus and hypertension. Community. Dent. Oral. Epidemiol. 2000; 28: 373-381.
41. Soell M., Feki A., Hannig M., Sano H., Pinget M., Selimovic D. Chromogranin A detection in saliva of type 2 diabetes patients. Bosn. J. Basic. Med. Sci. 2010; 10(1):2-8.
42. Fischer T.W., Slominski A., Zmijewski M.A., Reiter R.J. Paus R. Melatonin as a major skin protectant: from free radical scavenging to DNA damage repair. Exp. Dermatol. 2008; 17: 713-730.
43. Gümüs P., Buduneli N., Cetinkalp S. et al. Salivary antioxidants in patients with type 1 or 2 diabetes and inflammatory periodontal disease: a case-control study. J. Periodontol. 2009; 80:1440-1446.
44. Cutando A., Gómez-Moreno G., Villalba J., Ferrera M.J., Escames G. Acuña-Castroviejo D. Relationship between salivary melatonin levels and periodontal status in diabetic patients. J. Pineal. Res. 2003; 35: 239-244.
45. Costa P.P., Trevisan G.L., Macedo G.O. et al. Salivary interleu-kin-6, matrix metalloproteinase-8, and osteoprotegerin in patients with periodontitis and diabetes. J. Periodontol. 2010; 81: 384-391.
46. Collin H.L., Sorsa T., Meurman J.H. Salivary matrix metallopro-teinase (MMP-8) levels and gelatinase (MMP-9) activities in pa- tients with type 2 diabetes mellitus. J. Periodontal. Res. 2000; 35: 259-265.
47. Barrientos S., Stojadinovic O., Golinko M.S., Brem H., Tomic-Ca-nic M. Growth factors and cytokines in wound healing. Wound. Repair. Regen. 2008; 16: 585-601.
48. Blakytny R., Jude E.B. The molecular biology of chronic wounds and delayed healing in diabetes. Diabet. Med. 2006; 23: 594-608.
49. Grant M., Jerdan J., Merimee T.J. Insulin-like growth factor-i modulates endothelial cell chemotaxis. J. Clin. Endocrinol. Metab. 1987; 65: 370-371.
50. Kratz G., Lake M., Ljungstrom K., Forsberg G., Haegerstand A., Gidlund M. Effect of recombinant IGF binding protein-i on primary cultures of human keratinocytes and fibroblasts: selective enhancement of IGF-1 but not IGF-2 induced cell profileration. Exp. Cell. Res. 1992; 202: 381-385.
51. Bhora F.Y., Dunkin B.J., Batzri S., Aly H.M., Bass B.L., Sidawy A.N., Harmon J.W. Effect of growth factors on cell proliferation and epithelialization in human skin. J. Surg. Res. 1995; 59: 236-244.
52. Brown D.L., Kane C.D., Chernausek S.D., Greenhalgh D.G. Differential expression and localization of insulin-like growth factors I and II in cutaneous wounds of diabetic and non-diabetic mice. Am. J. Pathol. 1997; 151: 715-724.
53. Bitar M.S. Insulin and glucocorticoid-dependent suppression of the IGF-I system in diabetic wounds. Surgery 2000; 127: 687-695.
54. Bitar M.S., Labbad Z.N. Transforming growth factor-β and insulin-like growth factor I in relation to diabetes-induced impairment of wound healing. J. Surg. Res. 1996; 61:113-119.
55. Blakytny R., Jude E.B., Gibson J.M., Boulton A.J.M., Ferguson M.W.J. Lack of insulin-like growth factor I (IGF I) in the basal ke-ratinocyte layer of diabetic skin and diabetic foot ulcers. J. Pathol. 2000; 190: 589-594.
56. Roberts A.B. Transforming growth factor-β: activity and efficacy in animal models of wound healing. Wound. Rep. Regen. 1995; 3: 408-418.
57. Steed D.L. The role of growth factors in wound healing. Surg. Clin. North. Am. 1997; 77: 575-586.
58. Jude E.B., Blakytny R., Bulmer J., Boulton A.J.M., Ferguson M.W.J. Transforming growth factor-β1, -2, -3 and receptor type I and II in diabetic foot ulcers. Diabet. Med. 2002; 19:440-447.
59. Schmid P., Cox D., Bilbe G. et al. TGF-βs and TGF-β Type II receptor in human epidermis: differential expression in acute and chronic skin wounds. J. Pathol. 1993; 171:191-197.
60. Jude E.B., Boulton A.J.M., Ferguson M.W.J., Appleton I. The role of nitric oxide synthase isoforms and arginase in the pathogenesis of diabetic foot ulcers: possible modulatory effects by transforming growth factor β1. Diabetologia. 1999; 42: 748-757.
61. Castronuovo J.J. Jr., Ghobrial I., Giusti A.M., Rudolph S., Smiell J.M. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel. Am. J. Surg. 1998; 176: 61S-67S.
62. Doxey D.L., Ng M.C., Dill R.E., Iacopino A.M. Platelet-derived growth factor levels in wounds of diabetic rats. Life. Sci. 1995; 57: 1111-1123.
63. Beer H.D., Longaker M.T., Werner S. Reduced expression of PDGF and PDGF receptors during impaired wound healing. J. Invest. Dermatol. 1997; 109:132-138.
64. Soma Y., Grotendorst G.R. TGF-β stimulates primary human skin fibroblast DNA synthesis via an autocrine production of PDGF-related peptides. J. Cell. Physiol. 1989; 140: 246-253.
65. Matsuda H., Kannan Y., Ushio H. et al. Nerve growth factor induces development of connective tissue-type mast cells in vitro from murine bone marrow cells. J. Exp. Med. 1991; 174: 7-14.
66. Cantarella G., Lempereur L., Presta M. et al. Nerve growth fac-tor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J 2002; 16:1307-1309.
67. Di Marco E., Marchisio P.C., Bondanza S., Franzi A.T., Cancedda R., De Luca M. Growth-regulated synthesis and secretion of biologically active nerve growth factor by human keratinocytes. J. Biol. Chem. 1991; 266: 21718-21722.
68. Bonini S., Rasi G., Bracci-Laudiero M.L., Procoli A. Aloe L. Nerve growth factor: neurotrophin or cytokine? Int. Arch. Allergy. Immunol. 2003; 131: 80-84.
69. Graiani G., Emanueli C,. Desortes E et al. Nerve growth factor promotes reparative angiogenesis and inhibits endothelial apop-tosis in cutaneous wounds of type 1 diabetic mice. Diabetologia. 2004; 47:1047-1054.
70. Di Marco E., Mathor M., Bondanza S. et al. Nerve growth factor binds to normal human keratinocytes through high- and low-affinity receptors and stimulates their growth by a novel autocrine loop. J. Biol. Chem. 1993; 268: 22838-22846.
71. Ehrhard P.B., Ganter U., Bauer J., Otten U. Expression of functional trk protooncogene in human monocytes. Proc. Natl. Acad. SciUSA 1993; 90: 5423-5427.
72. Kannan Y., Ushio H., Koyama H. et al. 2.5S nerve growth factor enhances survival, phagocytosis, and superoxide production of murine neutrophils. Blood. 1991; 77:1320-1325.
73. Fernyhough P., Diemel L.T., Hardy J., Brewster W.J., Mohiuddin L.Tomlinson D.R. Human recombinant nerve growth factor replaces deficient neurotrophic support in the diabetic rat. Eur. J. Neurosci. 1995; 7:1107-1110.
74. Riaz S., Malcangio M., Miller M., Tomlinson D.R. A vitamin D3 derivative (CB1093) induces nerve growth factor and prevents neurotrophic deficits in streptozotocin-diabetic rats. Diabetologia. 1999; 42:1308-1313.
75. Anand P., Terenghi G., Warner G., Kopelman P.G., Williams-Chestnut R.E. Sinicropi D.V. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat. Med. 1996; 2: 703-707.
76. Yiangou Y., Facer P., Sinicropi D.V. et al. Molecular forms of NGF in human and rat neuropathic tissues: decreased NGF precursor-like immunoreactivity in human diabetic skin. J. Peripher. Nerv. Syst. 2002; 7:190-197.
77. Muangman P., Muffley L.A., Anthony J.P. et al. Nerve growth factor accelerates wound healing in diabetic mice. Wound. Repair. Regen. 2004; 12:44-52.
78. Werner S., Breeden M., Hubner G., Greenhalgh D.G., Longaker M.T. Induction of keratinocyte growth factor expression is reduced and delayed during wound healing in the genetically diabetic mouse. J. Invest. Dermatol.1994; 103:469-473.
79. Fahey T.J. 3rd, Sadaty A., Jones W.G. 2nd, Barber A., Smoller B., Shires G.T. Diabetes impairs the late inflammatory response to wound healing. J. Surg. Res. 1991; 50: 308-313.
80. Kimura T., Nakamura J. Health-related quality of life in outpatients of a psychosomatic medicine clinic: a pilot survey in Japan. Tokai. J. Exp. Clin. Med. 2004; 29:135-141.
81. Fisher E.B., Uorpe C.T., Devellis B.M., Devellis R.F. Healthy coping, negative emotions, and diabetes management: a systematic review and appraisal. Diabetes. Educ. 2007; 33:1080-1103.
82. Godbout J.P., Glaser R. Stress-induced immune dysregulation: implications for wound healing, infectious disease and cancer. J. Neuroimmune. Pharmacol. 2006; 1:421-427.
83. Boyapati L., Wang H.L. Ue role of stress in periodontal disease and wound healing. Periodontol 2000. 2007, 44:195-210.